Poseida Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$226.5M
Industry:Biotech
Founded:2015
Lead Investor(s):Longitude Capital
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

    0
  • Poseida Therapeutics received $30.0M in venture funding in April 2018.
  • 0
  • Poseida Therapeutics's total funding is $226.5M.

Employee Data

  • Poseida Therapeutics has 63 Employees.
  • Poseida Therapeutics grew their employee count by 43% last year.
  • Poseida Therapeutics currently has 11 job openings.

What Is Poseida Therapeutics?

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.

keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals

63

Number of Employees

N/A

Revenue (est)

11

Current Jobs

43%

Employee Growth %

$226.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
$7.4M6944%
Rigel Pharmaceu...
$40.5M2714%
ProTrials Resea...
$25.6M1703%
Advanced Cell D...
$23.9M1668%
CellMax Life
$10M379%$9M
Atreca
$10.7M8117%
Full Spectrum A...
$5.7M395%
Pipette.com/Acc...
N/AN/A
Irvine Scientif...
$29.1M2059%
Talis Biomedica...
$8.1M544%

Poseida Therapeutics News

09/03/2019 - Biotech IPO and M&A predictions from Jefferies analyst ...

More about Poseida Therapeutics: The San Diego-based biopharmaceutical company is developing CAR-T treatments, which harness the ...

04/22/2019 - Poseida Therapeutics Raises $142 Million in Series C Financing

SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging ...

09/03/2019 - Top 10 Companies Leveraging Gene Editing in 2019

Editas and Intellia, like CRISPR Therapeutics, reached 12-month lows .... Poseida Therapeutics, $226.5 million, Novartis Pharma AG invested ...

Poseida Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-17$30.0MAMalin Corporation plcArticle
2015-12-29$23.0MUndisclosedArticle
2018-04-05$30.0MBLongitude CapitalArticle

Poseida Therapeutics Executive Hires

DateNameTitleReference
2017-01-04Debra GessnerVP Regulatory AffairsArticle
2018-02-06Martin GiedlinVice President, Technical OperationsArticle
2018-03-01Mark Gergenchief business officer and chief financial officer.Article
2018-10-10Marcy GrahamVice President, Corporate AffairsArticle